Over 100 types of cellular RNA modifications, N6-methyladenosine (m6A) is the most abundant posttranscriptional RNA modification on eukaryote RNAs[7–9]. The functions of m6A in mRNA include nucleartransport, splicing, stability and translation [10–14].However, the m6A function in long non-coding RNA islimit to report. The nuclear-enriched abundant transcript 1(NEAT1) is an overexpressed long non-codingRNA in many human cancer types [15]. The higher expression of NEAT1 is significantly associated with worsesurvival in cancer patients [15, 16]. NEAT1 is responsiblefor several cancer clinical features: patient survival, metastasis, recurrence, stem cell-like phenotype [16].Knockdown of NEAT1 can decrease the malignant behavior of tumor cells for breast cancer [17, 18], hepatocellular carcinoma [19], laryngeal squamous cellcarcinoma [20], lung cancer [21], glioma [22], prostatecancer [23], and skin cancer [24]. NEAT1 is identified asan essential component of nuclear paraspeckles [25] andmediates transcription [26, 27]. NEAT1 is transcribedfrom familial tumor syndrome multiple endocrine neoplasia type I loci and encodes two transcriptional variants, NEAT1–1 (~ 3.7 kb) and NEAT1–2 (~ 22.7 kb) [28].NEAT1–1 serves as the ERα-inducible oncogenic targetand promotes the cancer progression in castrateresistant prostate cancer (CRPC) [23]. On the contrary,NEAT1–1 can be regulated by p53 to suppress the cancer transformation in pancreatic cancer